Skip to content

WHWK WHWK Preferred Stock

Preferred Stock at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$0

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's preferred stock?
WHWK (WHWK) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.